WORLDANTI-DOPING
AGENCY仮訳

play true

世界アンチ・ドーピング規程（The World Anti-doping Code）

2007年禁止リスト国際基準(The 2007 Prohibited List International Standard)（2007年１月１日版）(Update 1 January 2007)
本リストは、2007年１月１日に発効するスポーツ振興くじ助成事業

財団法人

日本アンチ・ドーピング機構

THE WORLD ANTI-DOPING CODE
The 2007 Prohibited List International Standardଲ ‫ ٮ‬ͺ ϋ Ι ¦ Ρ Ȝ ά ϋ Έ ܰ ೾!
3118 ා޺গςΑΠͅ‫࣭̳ͥ۾‬ष‫ܖ‬੔!

‫ޟ‬WADA code ߪ⧷ᢥ ߇ේᧄߣߥࠅ߹ߔ‫ⷙᧄޕ‬⒟ߩ⧷ᢥߣ๺ᢥߦᏅ⇣߇޽ࠆ႐วߦߪ‫⧷ޔ‬ᢥ߇ఝవߐࠇ߹ߔ‫ޕ‬‫ޠ‬

2007 ා 1 ࠮ 1 ඾อ࢘
2007 ᐕ 1 ᦬⊒ⴕ
⽷࿅ᴺੱ ᣣᧄࠕࡦ࠴࡮࠼࡯ࡇࡦࠣᯏ᭴઒⸶਎⇇ࠕࡦ࠴࡮࠼࡯ࡇࡦࠣⷙ⒟
㩿㪫㪿㪼㩷㪮㫆㫉㫃㪻㩷㪘㫅㫋㫀㪄㪛㫆㫇㫀㫅㪾㩷㪚㫆㪻㪼㪀㩷 ᐕ⑌ᱛ࡝ࠬ࠻࿖㓙ၮḰ(The 2007 Prohibited List International Standard)













 ᐕ  ᦬  ᣣߦ⊒ലߔࠆ (This List shall come into effective on 1 January 2007)

THE 2007 PROHIBITED LISTWORLD ANTI-DOPING CODE
Valid 1 January 2007

The use of any drug should be limited to medically justified indications
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES(IN-AND OUT-OF-COMPETITION)
PROHIBITED SUBSTANCES
S1. ANABOLIC AGENTS
Anabolic agents are prohibited.
1. Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS, including:1-androstendiol (5α-androst-1-ene-3β,17β-diol);
1-androstendione (5α-androst-1-ene-3,17-dione);bolandiol (19-norandrostenediol);bolasterone;boldenone;boldione (androsta-1,4-diene-3,17-dione);calusterone;clostebol;
danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole);
dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol);
drostanolone;
ethylestrenol (19-nor-17α-pregn-4-en-17-ol);fluoxymesterone;
formebolone;furazabol (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan);gestrinone;
4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one);mestanolone;
mesterolone;metenolone;methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one);methandriol;1ᐕ⑌ᱛ࡝ࠬ࠻࿖㓙ၮḰ㧔ᣣᧄ૕⢒දળ࠼࡯ࡇࡦࠣ࠺࡯࠲ࡌ࡯ࠬ૞ᚑ⃰઒⸶㧕ᐕ᦬ᣣ⊒ല ޿߆ߥࠆ⮎‛߽‫ޔ‬කቇ⊛ߦᱜᒰߥㆡᔕߦ㒢ߞߡ૶↪ߐࠇߥߌࠇ߫ߥࠄߥ޿‫ޕ‬Σ㧚Ᏹߦ⑌ᱛߐࠇࠆ‛⾰ߣᣇᴺ㧔┹ᛛળᬌᩏ෸߮┹ᛛᄖᬌᩏ㧕ࢲએ࿜૏
S1 Ⱞ⊕หൻ⮎Ⱞ⊕หൻ⮎ߪ⑌ᱛߐࠇࠆ‫ޕ‬

1. Ⱞ⊕หൻ↵ᕈൻ䉴䊁䊨䉟䊄⮎ (AAS)a. ᄖ࿃ᕈ* AAS㧧଀ߣߒߡਅ⸥ߩ߽ߩ߇޽ࠆ‫ޕ‬1-ǢȳȉȭǹȆȳǸǪȸȫ㧔5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3Ǫ, 17Ǫ-ࠫࠝ࡯࡞㧕㧧1-ǢȳȉȭǹȆȳǸǪȳ㧔5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧ȜȩȳǸǪȸȫ㧔19-ࡁ࡞ࠕࡦ࠼ࡠࠬ࠹ࡦࠫࠝ࡯࡞㧕㧧ȜȩǹȆȭȳ㧧ȜȫȇȎȳ㧧
ȜȫǸǪȳ㧔ࠕࡦ࠼ࡠࠬ࠲-1, 4-ࠫࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧ǫȫǹȆȭȳ㧧ǯȭǹȆȜȸȫ㧧ȀȊǾȸȫ㧔17ǩ-ࠛ࠴࠾࡞-17Ǫ-ࡅ࠼ࡠࠠࠪࠕࡦ࠼ࡠࠬ࠻-4-ࠛࡁ[2, 3-d]ࠗ࠰ࠠࠨ࠱࡯࡞㧕㧧ȇȒȉȭǯȭȭȡȁȫȆǹȈǹȆȭȳ㧔4-ࠢࡠࡠ-17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠕࡦ࠼ࡠࠬ࠲-1, 4-ࠫࠛࡦ-3-ࠝࡦ㧕㧧ȇǽǭǷȡȁȫȆǹȈǹȆȭȳ㧔17ǩ-ࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠻-2-ࠛࡦ-17Ǫ-ࠝ࡯࡞㧕㧧ȉȭǹǿȎȭȳ㧧ǨȁȫǨǹȈȬȎȸȫ㧔19-ࡁ࡞-17ǩ-ࡊ࡟ࠣࡦ-4-ࠛࡦ-17-ࠝ࡯࡞㧕㧧ȕȫǪǭǷȡǹȆȭȳ㧧ȕǩȫȡȜȭȳ㧧ȕȩǶȜȸȫ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠲ࡁ [2, 3-㨏]-ࡈ࡜ࠩࡦ㧕㧧ǲǹȈȪȎȳ㧧4-ȒȉȭǭǷȆǹȈǹȆȭȳ㧔4, 17Ǫ-ࠫࡅ࠼ࡠࠠࠪࠕࡦ࠼ࡠࠬ࠻-㧠-ࠛࡦ-3-ࠝࡦ㧕㧧ȡǹǿȎȭȳ㧧ȡǹȆȭȭȳ㧧ȡȆȎȭȳ㧧
ȡǿȳǸǨȎȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠕࡦ࠼ࡠࠬ࠲-1, 4-ࠫࠛࡦ-3-ࠝࡦ㧕㧧ȡǿȳȉȪǪȸȫ㧧
1

methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol);
methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one);methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one);methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one);methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one);methyltestosterone;
mibolerone;
nandrolone;
19-norandrostenedione (estr-4-ene-3,17-dione);norboletone;
norclostebol;
norethandrolone;
oxabolone;oxandrolone;
oxymesterone;
oxymetholone;
prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol);quinbolone;
stanozolol;
stenbolone;
1-testosterone (17β-hydroxy-5α-androst-1-en-3-one);tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one);
trenbolone and other substances with a similar chemical structure or similar
biological effect(s).
b. Endogenous** AAS:
androstenediol (androst-5-ene-3β,17β-diol);androstenedione (androst-4-ene-3,17-dione);dihydrotestosterone (17β-hydroxy-5α-androstan-3-one);prasterone (dehydroepiandrosterone, DHEA);
testosterone and the following metabolites and isomers:
5α-androstane-3α,17α-diol;
5α-androstane-3α,17β-diol;
5α-androstane-3β,17α-diol;
5α-androstane-3β,17β-diol;
androst-4-ene-3α,17α-diol;
androst-4-ene-3α,17β-diol;
androst-4-ene-3β,17α-diol;
androst-5-ene-3α,17α-diol;
androst-5-ene-3α,17β-diol;
androst-5-ene-3β,17α-diol;2ȡǿǹȆȭȳ㧔2ǩ,17ǩ-ࠫࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠲ࡦ-3-ࠝࡦ-17Ǫ-ࠝ࡯࡞㧕㧧ȡȁȫǸǨȎȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠛࠬ࠻࡜-4, 9-ࠫࠛࡦ-3-ࠝࡦ㧕㧧ȡȁȫ-1-ȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞-5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3-ࠝࡦ㧕㧧ȡȁȫȎȫȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠛࠬ࠻࡞-4-ࠛࡦ-3-ࠝࡦ㧕㧧ȡȁȫȈȪǨȎȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-17ǩ-ࡔ࠴࡞ࠛࠬ࠻࡜-4, 9, 11-࠻࡝ࠛࡦ-3-ࠝࡦ㧕㧧ȡȁȫȆǹȈǹȆȭȳ㧧ȟȜȬȭȳ㧧
Ȋȳȉȭȭȳ㧧19-ȎȫǢȳȉȭǹȆȳǸǪȳ㧔ࠛࠬ࠻࡞-㧠-ࠛࡦ 3, 17-ࠫࠝࡦ㧕㧧ȎȫȜȬȈȳ㧧ȎȫǯȭǹȆȜȸȫ㧧ȎȫǨǿȳȉȭȭȳ㧧ǪǭǵȜȭȳ㧧Ǫǭǵȳȉȭȭȳ㧧ǪǭǷȡǹȆȭȳ㧧ǪǭǷȡȈȭȳ㧧ȗȭǹǿȎǾȸȫ㧔[3, 2-㨏]ࡇ࡜࠱࡯࡞-5ǩ-ࠛ࠴ࠝࠕࡠࠦ࡜ࡦ-17Ǫ-࠹࠻࡜ࡅ࠼ࡠࡇ࡜ࡁ࡯࡞㧕㧧ǭȳȜȭȳ㧧
ǹǿȎǾȭȸȫ㧧ǹȆȳȜȭȳ㧧1-ȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-5ǩ-ࠕࡦ࠼ࡠࠬ࠻-1-ࠛࡦ-3-ࠝࡦ㧕㧧ȆȈȩȒȉȭǲǹȈȪȎȳ㧔18ǩ-ࡎࡕ-ࡊ࡟ࠣ࠽-4, 9, 11-࠻࡝ࠛࡦ-17Ǫ-ࠝ࡯࡞-3-ࠝࡦ㧕㧧ȈȬȳȜȭȳ෸߮㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩ‫ޕ‬b. ౝ࿃ᕈ** AAS㧦ǢȳȉȭǹȆȳǸǪȸȫ㧔ࠕࡦ࠼ࡠࠬ࠻-5-ࠛࡦ-3Ǫ, 17Ǫ-ࠫࠝ࡯࡞㧕㧧ǢȳȉȭǹȆȳǸǪȳ㧔ࠕࡦ࠼ࡠࠬ࠻-4-ࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧ǸȒȉȭȆǹȈǹȆȭȳ㧔17Ǫ-ࡅ࠼ࡠࠠࠪ-5ǩ-ࠕࡦ࠼ࡠࠬ࠲ࡦ-3-ࠝࡦ㧕㧧ȗȩǹȆȭȳ㧔࠺ࡅ࠼ࡠࠛࡇࠕࡦ࠼ࡠࠬ࠹ࡠࡦ‫ޔ‬DHEA)㧧
ȆǹȈǹȆȭȳ෸߮ਅ⸥ߩઍ⻢‛ߣ⇣ᕈ૕
5-Ǣȳȉȭǹǿȳ-3, 17-ǸǪȸȫᲵ
5-Ǣȳȉȭǹǿȳ-3, 17-ǸǪȸȫᲵ
5-Ǣȳȉȭǹǿȳ-3, 17-ǸǪȸȫᲵ
5-Ǣȳȉȭǹǿȳ-3, 17-ǸǪȸȫᲵǢȳȉȭǹȈ-4-Ǩȳ-3, 17-ǸǪȸȫᲵǢȳȉȭǹȈ-4-Ǩȳ-3, 17-ǸǪȸȫᲵǢȳȉȭǹȈ-4-Ǩȳ-3, 17-ǸǪȸȫᲵǢȳȉȭǹȈ-5-Ǩȳ-3, 17-ǸǪȸȫᲵǢȳȉȭǹȈ-5-Ǩȳ-3, 17-ǸǪȸȫᲵǢȳȉȭǹȈ-5-Ǩȳ-3, 17-ǸǪȸȫᲵ
2

4-androstenediol (androst-4-ene-3β,17β-diol);
5-androstenedione (androst-5-ene-3,17-dione);
epi-dihydrotestosterone;
3α-hydroxy-5α-androstan-17-one;
3β-hydroxy-5α-androstan-17-one;
19-norandrosterone;
19-noretiocholanolone.
Where an anabolic androgenic steroid is capable of being produced endogenously,a Sample will be deemed to contain such Prohibited Substance where theconcentration of such Prohibited Substance or its metabolites or markers and/or
any other relevant ratio(s) in the Athlete’s Sample so deviates from the range ofvalues normally found in humans that it is unlikely to be consistent with normal
endogenous production. A Sample shall not be deemed to contain a Prohibited
Substance in any such case where an Athlete proves that the concentration of theProhibited Substance or its metabolites or markers and/or the relevant ratio(s) in
the Athlete’s Sample is attributable to a physiological or pathological condition.
In all cases, and at any concentration, the Athlete’s sample will be deemed tocontain a Prohibited Substance and the laboratory will report an Adverse
Analytical Finding if, based on any reliable analytical method (e.g. IRMS), thelaboratory can show that the Prohibited Substance is of exogenous origin. In suchcase, no further investigation is necessary.
If a value in the range of levels normally found in humans is reported and thereliable analytical method (e.g. IRMS) has not determined the exogenous origin of
the substance, but if there are indications, such as a comparison to endogenous
reference steroid profiles, of a possible Use of a Prohibited Substance, further
investigation shall be conducted by the relevant Anti-Doping Organization byreviewing the results of any previous test(s) or by conducting subsequent test(s),in order to determine whether the result is due to a physiological or pathologicalcondition, or has occurred as a consequence of the exogenous origin of a
Prohibited Substance.
When a laboratory has reported a T/E ratio greater than four (4) to one (1) andany reliable analytical method (e.g. IRMS) applied has not determined theexogenous origin of the substance, further investigation may be conducted by areview of previous tests or by conducting subsequent test(s), in order todetermine whether the result is due to a physiological or pathological condition, or
has occurred as a consequence of the exogenous origin of a Prohibited Substance.
If a laboratory reports, using an additional reliable analytical method (e.g. IRMS),
that the Prohibited Substance is of exogenous origin, no further investigation isnecessary and the Sample will be deemed to contain such Prohibited Substance.
When an additional reliable analytical method (e.g. IRMS) has not been appliedand a minimum of three previous test results are not available, a longitudinal
profile of the Athlete shall be established by performing a minimum of three noadvance notice tests in a period of three months by the relevant Anti-Doping
Organization. If the longitudinal profile of the Athlete established by thesubsequent tests is not physiologically normal, the result shall be reported as anAdverse Analytical Finding.
34-ǢȳȉȭǹȆȳǸǪȸȫ㧔ࠕࡦ࠼ࡠࠬ࠻-4-ࠛࡦ-3Ǫ, 17Ǫ-ࠫࠝ࡯࡞㧕㧧5-ǢȳȉȭǹȆȳǸǪȳ㧔ࠕࡦ࠼ࡠࠬ࠻-5-ࠛࡦ-3, 17-ࠫࠝࡦ㧕㧧ǨȔ-ǸȒȉȭȆǹȈǹȆȭȳ㧧
3-ȒȉȭǭǷ-5-Ǣȳȉȭǹǿȳ-17-Ǫȳ㧧
3-ȒȉȭǭǷ-5-Ǣȳȉȭǹǿȳ-17-Ǫȳ㧧
19-ȎȫǢȳȉȭǹȆȭȳ㧧19-ȎȫǨȁǪǳȩȎȭȳ‫ޕ‬਄⸥ߩࠃ߁ߥ૕ౝߢ⥄ὼߦߟߊࠄࠇࠆⰮ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎ߦߟ޿ߡߪ‫ޔ‬ᬌ૕ਛߩ⑌ᱛ‛⾰‫ߘޔ‬ߩઍ⻢‛෶ߪࡑ࡯ࠞ࡯ߩỚᐲ߅ࠃ߮㧛߹ߚߪߘߩઁ㑐ㅪ‛⾰ߣߩᲧ₸߇ᱜᏱ▸࿐߆ࠄ߆ߌ㔌ࠇ‫ޔ‬ᱜᏱߦౝ࿃ᕈߦ↥↢ߐࠇߚ‛⾰ߣߪ್ᢿߢ߈ߥ޿႐ว‫ޔ‬ᬌ૕ߦߪ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣߺߥߐࠇࠆ‫ޔߒߛߚޕ‬⑌ᱛ‛⾰‫ߩߘޔ‬ઍ⻢‛෶ߪࡑ࡯ࠞ࡯ߩỚᐲ߅ࠃ߮㧛߹ߚߪߘߩઁ㑐ㅪ‛⾰ߣߩᲧ₸߇↢ℂ⊛޽ࠆ޿ߪ∛⊛⁁ᘒߦ⿠࿃ߔࠆߎߣࠍ┹ᛛ⠪߇┙⸽ߒߚ႐ว‫ޔ‬ᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣߪߺߥߐࠇߥ޿‫ޕ‬޿߆ߥࠆ႐วߦ߅޿ߡ߽‫ࠆߥ߆޿ޔߚ߹ޔ‬Ớᐲߢ޽ߞߡ߽ା㗬ᕈߩ㜞޿ಽᨆᣇᴺ(IRMS*╬)ߦၮߠ޿
ߡಽᨆᯏ㑐߇ߘߩ⑌ᱛ‛⾰߇ᄖ࿃ᕈ↱᧪ߢ޽ࠆߎߣࠍ⸽᣿ߢ߈ࠆ႐วߦߪ‫ޔ‬ᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ
޿ࠆߣߺߥߐࠇࠆߩߢ‫ޔ‬ಽᨆᯏ㑐ߪ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߔࠆߎߣߦߥࠆ‫ߥ߁ࠃߩߘޕ‬႐วߦߪㅊട⺞ᩏߪᔅⷐߣߐࠇߥ޿‫ޕ‬*IRMS㧦ห૏૕Ყ⾰㊂ಽᨆᴺᬌᩏ୯߇ᱜᏱ▸࿐ౝߢ޽ࠅ‫ޔ‬ା㗬ߢ߈ࠆಽᨆᣇᴺ(IRMS ╬)ߢᄖ࿃ᕈߢ޽ࠆߎߣ߇᳿ቯߢ߈ߥ޿႐วߢ
߽‫ޔ‬ෳᾖߔߴ߈ࠬ࠹ࡠࠗ࠼ࡊࡠࡈࠔࠗ࡞ߣᲧセߒߡ‫⑌ޔ‬ᱛ‛⾰ࠍ૶↪ߒߚน⢻ᕈ߇޽ࠆߣ޿߁ళ୥߇޽
ࠆߣ್ᢿߐࠇࠆ႐ว‫ޔ‬㑐ㅪࠕࡦ࠴࡮࠼࡯ࡇࡦࠣᯏ㑐ߪ‫⚿ߩߘޔ‬ᨐ߇↢ℂ⊛޽ࠆ޿ߪ∛⊛⁁ᘒߦ⿠࿃ߔࠆ
߆‫ߪߚ߹ޔ‬ᄖ࿃ᕈߩⰮ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎ߦ⿠࿃ߔࠆ߆ࠍ್ᢿߔࠆὑߦ‫ޔ‬ㆊ෰ߩ⚿ᨐࠍᬌ⸛ߔࠆ‫ޔ‬޽ࠆ޿ߪㅊ〔ᬌᩏࠍⴕ߁‫ޕ‬ಽᨆᯏ㑐߆ࠄ‫ޔ‬ዩਛߩ T/E Ყ߇ 4 ࠍ⿥߃ߡႎ๔ߐࠇ‫ޔ‬ା㗬ߢ߈ࠆಽᨆᣇᴺ(IRMS ╬)ߦࠃߞߡ߽ᄖ࿃
ᕈߩ⑌ᱛ‛⾰ߢ޽ࠆߣ್ᢿߢ߈ߥ޿႐ว‫ߩߘޔ‬Ყ₸߇↢ℂ⊛࡮∛⊛⁁ᘒߦ⿠࿃ߔࠆ߆޽ࠆ޿ߪᄖ࿃ᕈߩ
Ⱞ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎↱᧪ߢ޽ࠆ߆ุ߆ࠍ್ᢿߔࠆߚ߼‫ޔ‬ㆊ෰ߩ⚿ᨐࠍᬌ⸛ߔࠆ‫ߪ޿ࠆ޽ޔ‬ㅊ〔ᬌᩏߦࠃࠅߐࠄߦ⺞ᩏߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ಽᨆᯏ㑐߆ࠄႎ๔ߐࠇߚ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐ߇‫ޔ‬ା㗬ߩ߅ߌࠆಽᨆᣇᴺ(IRMS ╬)ࠍ↪޿ߡᄖ࿃ᕈߩⰮ⊕หൻ↵ᕈൻࠬ࠹ࡠࠗ࠼⮎ߢ޽ࠆߎߣࠍ⸽᣿ߒߡ޿ࠆ႐ว
ߦߪ‫ޔ‬ㅊട⺞ᩏߪᔅⷐߣߐࠇߕ‫ޔ‬ᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣߺߥߐࠇࠆ‫ޕ‬ା㗬ᕈߩ޽ࠆಽᨆᣇᴺ(IRMS ╬)߇ㅊട⊛ߦⴕࠊࠇߕ‫ᦨߟ߆ޔ‬ૐㆊ෰ 3 ࿁ߩ⚿ᨐ߇೑↪ߢ߈ߥ޿႐ว‫ޔ‬㑐ㅪࠕࡦ࠴࡮࠼࡯ࡇࡦࠣ

ᯏ㑐ߪ 3 ࡩ᦬એౝߦዋߥߊߣ߽ 3 ࿁ߩ੍๔ήߒᬌᩏࠍታᣉߔࠆߎߣߦࠃߞߡᒰ⹥┹ᛛ⠪ߩ㐳ᦼ⊛ࡊࡠࡈࠔࠗ࡞ࠍ᣿ࠄ߆ߦߒߥߌࠇ߫ߥࠄߥ޿‫ࠄࠇߎޕ‬ㅊ〔ᬌᩏߦࠃߞߡ᣿ࠄ߆ߦߐࠇߚ┹ᛛ⠪ߩ㐳ᦼ⊛ࠬ࠹ࡠࠗ࠼ࡊࡠࡈࠔࠗ࡞߇↢ℂ⊛ߦᱜᏱߢߪߥ޿႐ว‫ޔ‬㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇߥߌࠇ߫ߥࠄ
ߥ޿‫ޕ‬

3

In extremely rare individual cases, boldenone of endogenous origin can beconsistently found at very low nanograms per milliliter (ng/mL) levels in urine.
When such a very low concentration of boldenone is reported by a laboratory andthe application of any reliable analytical method (e.g. IRMS) has not determinedthe exogenous origin of the substance, further investigation may be conducted bysubsequent tests. When an additional reliable analytical method (e.g. IRMS) has
not been applied, a longitudinal profile of the athlete shall be established by
performing a minimum of three no advance notice tests in a period of threemonths by the relevant Anti-Doping Organization. If the longitudinal profile of theAthlete established by the subsequent tests is not physiologically normal, theresult shall be reported as an Adverse Analytical Finding.
For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is
considered to be scientific and valid proof of exogenous origin of the Prohibited
Substance. In such case, no further investigation is necessary.
Should an Athlete fail to cooperate in the investigations, the Athlete’s Sample
shall be deemed to contain a Prohibited Substance.

4㕖Ᏹߦ⒘ߛ߇‫ޔ‬୘ੱߦࠃߞߡߪ‫ޔ‬ౝ࿃ᕈߩࡏ࡞࠺ࡁࡦ߇࠽ࡁࠣ࡜ࡓ㧛ࡒ࡝࡝࠶࠻࡞㧔ng/mL㧕ߩ࡟ࡌ࡞ߢ㕖ᏱߦૐỚᐲߢߪ޽ࠆ߇ዩਛߦᏱᤨᬌ಴ߐࠇࠆߎߣ߇޽ࠆ‫ߊߏߥ߁ࠃߩߘޕ‬ૐỚᐲߩࡏ࡞࠺ࡁࡦࠍ
ಽᨆᯏ㑐߇ႎ๔ߒ‫ޔ‬ା㗬ߩ߅ߌࠆಽᨆᣇᴺ(IRMS ╬)ߩㆡ↪ߦࠃߞߡ߽ࡏ࡞࠺ࡁࡦ߇ᄖ࿃ᕈ↱᧪ߢ޽ࠆߣ
್ᢿߐࠇߥ޿႐ว‫ޔ‬ㅊ〔ᬌᩏߦࠃࠅߐࠄߦ⺞ᩏߔࠆߎߣ߇ߢ߈ࠆ‫ޕ‬ା㗬ᕈߩ޽ࠆಽᨆᣇᴺ(IRMS ╬)߇ㅊട⊛ߦⴕࠊࠇߥ޿႐ว‫ޔ‬㑐ㅪࠕࡦ࠴࡮࠼࡯ࡇࡦࠣᯏ㑐ߪ 3 ࡩ᦬એౝߦዋߥߊߣ߽ 3 ࿁ߩ੍๔ήߒᬌᩏࠍᒰ
⹥┹ᛛ⠪ߦኻߒታᣉߒߥߌࠇ߫ߥࠄߥ޿‫৻ޕ‬ㅪߩᬌᩏࠍฃߌߚ┹ᛛ⠪ߩ㐳ᦼ⊛ࠬ࠹ࡠࠗ࠼ࡊࡠࡈࠔࠗ࡞
߇↢ℂ⊛ߦᱜᏱߢߪߥ޿႐ว‫ޔ‬㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇߥߌࠇ߫ߥࠄߥ޿‫ޕ‬19-ࡁ࡞ࠕࡦ࠼ࡠࠬ࠹ࡠࡦߦ㑐ߒߡߪ‫ޔ‬ಽᨆᯏ㑐ߦࠃߞߡႎ๔ߐࠇߚ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߪ⑌ᱛ‛⾰߇ᄖ࿃ᕈ↱᧪ߢ޽ࠆߎߣߩ⑼ቇ⊛߆ߟ᦭ലߥ⸽᜚ߣ⠨߃ࠄࠇࠆ‫ߥ߁ࠃߩߘޕ‬႐วߦߪㅊട⺞ᩏߪᔅⷐߣߐࠇߥ޿‫ޕ‬┹ᛛ⠪߇ߎߩ⺞ᩏ߳ߩදജࠍᕃߞߚ႐ว‫ޔ‬ᒰ⹥┹ᛛ⠪ߩᬌ૕ߦ⑌ᱛ‛⾰߇฽߹ࠇߡ޿ࠆߣ⷗ߥߐࠇࠆ
ߎߣߦߥࠆ‫ޕ‬4

2. Other Anabolic Agents, including but not limited to:
Clenbuterol,tibolone,

zeranol,zilpaterol.

For purposes of this section:*“exogenous” refers to a substance which is not ordinarily capable of being
produced by the body naturally.
**“endogenous” refers to a substance which is capable of being produced by the
body naturally.

S2. HORMONES AND RELATED SUBSTANCES
The following substances, including other substances with a similar chemical
structure or similar biological effect(s), and their releasing factors, are prohibited:
1. Erythropoietin (EPO);
2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1),
Mechano Growth Factors (MGFs);
3. Gonadotrophins (LH, hCG), prohibited in males only;
4. Insulin;
5. Corticotrophins.
Unless the Athlete can demonstrate that the concentration was due to aphysiological or pathological condition, a Sample will be deemed to contain a
Prohibited Substance (as listed above) where the concentration of the Prohibited
Substance or its metabolites and/or relevant ratios or markers in the Athlete’s
Sample so exceeds the range of values normally found in humans that it isunlikely to be consistent with normal endogenous production.
If a laboratory reports, using a reliable analytical method, that the Prohibited
Substance is of exogenous origin, the Sample will be deemed to contain a
Prohibited Substance and shall be reported as an Adverse Analytical Finding.
The presence of other substances with a similar chemical structure or similar
biological effect(s), diagnostic marker(s) or releasing factors of a hormone listed
above or of any other finding which indicate(s) that the substance detected is ofexogenous origin, will be deemed to reflect the use of a Prohibited Substance andshall be reported as an Adverse Analytical Finding.

S3. BETA-2 AGONISTSAll beta-2 agonists including their D- and L-isomers are prohibited.
As an exception, formoterol, salbutamol, salmeterol and terbutaline whenadministered by inhalation, require an abbreviated Therapeutic Use Exemption.
Despite the granting of any form of Therapeutic Use Exemption, a concentrationof salbutamol (free plus glucuronide) greater than 1000 ng/mL will be considered
an Adverse Analytical Finding unless the Athlete proves that the abnormal result
was the consequence of the therapeutic use of inhaled salbutamol.
52. 䈠䈱ઁ䈱Ⱞ⊕หൻ⮎䋻଀䈫䈚䈩ਅ⸥䈱䉅䈱䈏䈅䉎 ǯȬȳȖȆȭȸȫŴȁȜȭȳŴǼȩȎᲧȫŴǸȫȑȆȭȸȫߎߩ࠮࡚ࠢࠪࡦߦ߅޿ߡ‫ޔ‬**‫ޟ‬ᄖ࿃ᕈ(exogenous)‫ޔߪߣޠ‬ㅢᏱߪ૕ౝߢ⥄ὼߦߟߊࠄࠇᓧߥ޿‛⾰ࠍ޿߁‫ޕ‬**‫ޟ‬ౝ࿃ᕈ(endogenous)‫ޔߪߣޠ‬૕ౝߢ⥄ὼߦߟߊࠄࠇᓧࠆ‛⾰ࠍ޿߁‫ޕ‬S2. 䊖䊦䊝䊮䈫㑐ㅪ‛⾰
ਅ⸥ߩ‛⾰ߪ‫ޔ‬㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆߘߩઁߩ‛⾰෸߮ߘࠇࠄߩ᡼಴࿃ሶ߽
฽߼‫⑌ޔ‬ᱛߐࠇࠆ‫ޕ‬
 1. ǨȪǹȭȝǨȁȳᲢEPOᲣᲵ 2. ঺ᧈțȫȢȳᲢhGHᲣŴǤȳǹȪȳಮ঺ᧈ‫܇׆‬ᲢIGF-1 ╬ᲣŴೞ఺ႎ঺ᧈ‫܇׆‬ᲢMGFsᲣᲵ
 3. ǴȊȉȈȭȔȳ᫏ᲢLH, hCGᲣŴ↵ᕈߦ߅޿ߡߩߺ⑌ᱛᲵ
 4. ǤȳǹȪȳᲵ 5. ǳȫȁǳȈȭȔȳ᫏Ჵᬌ૕ਛߩ⑌ᱛ‛⾰෶ߪߘߩઍ⻢‛ߩỚᐲ߅ࠃ߮㧛߹ߚߪ㑐ㅪߩᲧ₸߿ࡑ࡯ࠞ࡯߇ࡅ࠻ߩᱜᏱ▸࿐ࠍㅺ⣕ߒᱜᏱߦౝ࿃ᕈߦ↥↢ߐࠇߚ‛⾰ߣߺߥߐࠇߥ޿႐ว‫┹ޔ‬ᛛ⠪߇ߘߩỚᐲ߇↢ℂ⊛⁁ᘒ޽ࠆ޿ߪ∛⊛⁁ᘒߦ⿠࿃ߔࠆߎߣࠍ⸽᣿ߒߥ޿㒢ࠅ‫┹ߩߘޔ‬ᛛ⠪ߩᬌ૕ਛߦ⑌ᱛ‛⾰㧔਄⸥೉᜼㧕߇฽߹ࠇߡ޿ࠆ
ߣߺߥߐࠇࠆ‫ޕ‬ಽᨆᯏ㑐߇ା㗬ߩ߅ߌࠆಽᨆᣇᴺߦࠃߞߡ⑌ᱛ‛⾰߇ᄖ࿃ᕈߢ޽ࠆߣႎ๔ߒߚ႐ว‫ޔ‬ᬌ૕ߪ⑌ᱛ‛⾰ࠍ฽ࠎߢ޿ࠆߣߺߥߐࠇ‫ޔ‬㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇࠆ‫ޕ‬ᬌ૕ਛߦ㘃ૃߩൻቇ᭴ㅧ߿↢‛ቇ⊛ലᨐࠍᜬߟઁߩ‛⾰‫⸻ޔ‬ᢿࡑ࡯ࠞ࡯㘃‫ޔ‬਄⸥ߦ೉᜼ߒߚࡎ࡞ࡕࡦ
ߩ᡼಴࿃ሶ߇ᬌ಴ߐࠇߚ႐ว‫ߪ޿ࠆ޽ޔ‬ᬌ಴‛⾰߇૕ᄖ↱᧪ߢ޽ࠆߎߣ߇᣿ࠄ߆ߦߐࠇߚ႐ว‫⑌ޔ‬ᱛ‛⾰ߩ૶↪ࠍ෻ᤋߔࠆ߽ߩߣߺߥߒ㧘ߘࠇࠄߪ㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡႎ๔ߐࠇࠆ‫ޕ‬

S3 䊔䊷䉺 2 ૞↪⮎ߔߴߡߩࡌ࡯࠲ 2 ૞↪⮎ߪ‫ ߩߘޔ‬D ૕෸߮ L ૕߽฽߼ߡ⑌ᱛߐࠇࠆ‫ޕ‬଀ᄖߣߒߡ‫߇ࡦ࡝࠲ࡉ࡞࠹ޔ࡞࡯ࡠ࠹ࡔ࡞ࠨޔ࡞࡯ࡕ࠲ࡉ࡞ࠨޔ࡞࡯ࡠ࠹ࡕ࡞ࠜࡈޔ‬ๆ౉૶↪ߐࠇࠆ႐วߦߪ‫⇛ޔ‬ᑼߩᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߩ↳⺧߇ᔅⷐߣߥࠆ‫ޕ‬޿߆ߥࠆᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎߇⹺߼ࠄࠇߡ޿ߡ߽‫ߩ࡞࡯ࡕ࠲ࡉ࡞ࠨޔ‬Ớᐲ(ࡈ࡝࡯ߣࠣ࡞ࠢࡠࡦ㉄ᛴว૕ߩỚᐲ)߇ 1000 ng / ml એ਄ߩ႐ว‫⇣ߩߘޔ‬Ᏹ୯߇ࠨ࡞ࡉ࠲ࡕ࡯࡞ๆ౉ߦࠃࠆᴦ≮⋡⊛ߩ⚿ᨐߢ޽ࠆߎߣࠍ┹ᛛ⠪߇┙⸽ߒߥ޿߆߉ࠅ‫ޔ‬㆑෻߇⇼ࠊࠇࠆಽᨆ⚿ᨐߣߒߡᛒࠊࠇࠆߎߣߦߥࠆ‫ޕ‬5

S4. AGENTS WITH ANTI-ESTROGENIC ACTIVITY
The following classes of anti-estrogenic substances are prohibited:
1. Aromatase inhibitors including, but not limited to, anastrozole,
letrozole, aminoglutethimide, exemestane, formestane, testolactone.
2. Selective Estrogen Receptor Modulators (SERMs) including, but notlimited to, raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to,clomiphene, cyclofenil, fulvestrant.

S5. DIURETICS AND OTHER MASKING AGENTS
Masking agents are prohibited. They include:
Diuretics*,
epitestosterone,probenecid,alpha-reductase inhibitors (e.g. finasteride,dutasteride),

plasma expanders (e.g. albumin,hydroxyethyl starch)dextran,and other substances with similar biological effect(s).
Diuretics include:
acetazolamide,
amiloride,bumetanide,canrenone,
chlorthalidone,
etacrynic acid,furosemide,
indapamide,
metolazone,
spironolactone,
thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide),triamterene, and other substances with a similar chemical structure or similar
biological effect(s) (except for drosperinone, which is not prohibited).
*

A Therapeutic Use Exemption is not valid if an Athlete’s urine contains a diuretic
in association with threshold or sub-threshold levels of a Prohibited Substance(s).

6S4. ᛫䉣䉴䊃䊨䉭䊮૞↪䉕᦭䈜䉎⮎‛ਅ⸥ߩ᛫ࠛࠬ࠻ࡠࠥࡦ૞↪ࠍ᦭ߔࠆ‛⾰ߪ⑌ᱛߐࠇࠆ‫ޕ‬1ᲨǢȭȞǿȸǼ᧹ܹᕤƱƠƯƸŴഏƷǋƷƕਫƛǒǕǔƕŴƜǕǒƴᨂ‫ܭ‬ƢǔǋƷưƸƳƍŵ
ǢȊǹȈȭǾȸȫŴȬȈȭǾȸȫŴǢȟȎǰȫȆȁȟȉŴǨǯǹȡǹǿȳŴ
ȕǩȫȡǹǿȳŴȆǹȈȩǯȈȳŵ
2Შᢠ৸ႎǨǹȈȭǲȳӖܾ˳ᛦራᕤᲢSERMsᲣƱƠƯƸŴഏƷǋƷƕਫƛǒǕǔƕŴƜǕǒƴᨂ‫ܭ‬ƢǔǋƷưƸƳƍŵ
ȩȭǭǷȕǧȳŴǿȢǭǷȕǧȳŴȈȬȟȕǧȳ
3ᲨƦƷ˂Ʒ৴ǨǹȈȭǲȳ˺ဇǛஊƢǔᕤཋƱƠƯƸŴഏƷǋƷƕਫƛǒǕǔƕŴƜǕǒƴᨂ‫ܭ‬ƢǔǋƷưƸƳƍŵ
ǯȭȟȕǧȳŴǷǯȭȕǧȋȫŴȕȫșǹȈȩȳȈŵ

S5. ೑ዩ⮎䈫ઁ䈱㓝⭁⮎㓝⭁⮎ߪ⑌ᱛߐࠇࠆ‫ޕ‬㓝⭁⮎ߦߪਅ⸥ߩ߽ߩ߇฽߹ࠇࠆ‫ޕ‬М‫ބ‬ᕤ*ŴǨȔȆǹȈǹȆȭȳŴ
ȗȭșȍǷȉŴ
-ᢩΨᣞእ᧹ܹᕤᲢȕǣȊǹȆȪȉŴȇȥǿǹȆȪȉ╬ᲣŴᘉ๶‫ف‬᣽ཋឋᲢǢȫȖȟȳŴȇǭǹȈȩȳŴȒȉȭǭǷǨȁȫȇȳȗȳ╬Უ෸߮㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩ‫ޕ‬೑ዩ⮎ߦߪ‫ޔ‬ਅ⸥ߩ߽ߩ߇฽߹ࠇࠆ㧧ǢǻǿǾȩȟȉŴ
ǢȟȭȪȉŴ
ȖȡǿȋȉŴ
ǫȳȬȎȳŴ
ǯȭȫǿȪȉȳŴ
ǨǿǯȪȳᣠŴȕȭǻȟȉŴ
ǤȳȀȑȟȉŴ
ȡȈȩǾȳŴ
ǹȔȭȎȩǯȈȳŴ
ȁǢǸȉ᫏ᲢșȳȉȭȕȫȡȁǢǸȉŴǯȭȭȁǢǸȉŴȒȉȭǯȭȭȁǢǸȉ╬ᲣŴȈȪǢȠȆȬȳŴ෸߮㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩ‫ޕ‬㧔ૉߒ‫⑌ߪࡦࡁ࡝ࡍࠬࡠ࠼ޔ‬ᱛ‛⾰ߦߪ฽߹ࠇߥ޿㧕*┹ᛛ⠪ߩዩਛߦ޽ࠆ⑌ᱛ‛⾰߇㑣୯᳓Ḱ޽ࠆ޿ߪ㑣୯᳓Ḱᧂḩߢሽ࿷ߒ‫ߟ߆ޔ‬೑ዩ⮎߇฽߹ࠇߡ޿
ߚᤨ‫ޔ‬ᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߪήലߣߥࠆ‫ޕ‬

6

PROHIBITED METHODS
M1. ENHANCEMENT OF OXYGEN TRANSFER
The following are prohibited:
1. Blood doping, including the use of autologous, homologous or heterologous
blood or red blood cell products of any origin.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including
but not limited to perfluorochemicals, efaproxiral (RSR13) and modified
haemoglobin products (e.g. haemoglobin-based blood substitutes,
microencapsulated haemoglobin products).

M2. CHEMICAL AND PHYSICAL MANIPULATION
1. Tampering, or attempting to tamper, in order to alter the integrity andvalidity of Samples collected during Doping Controls is prohibited. These
include but are not limited to catheterisation, urine substitution and/or
alteration.
2. Intravenous infusions are prohibited, except as a legitimate medical
treatment.

M3. GENE DOPING
The non-therapeutic use of cells, genes, genetic elements, or of the modulation ofgene expression, having the capacity to enhance athletic performance, isprohibited.

7ࢲએုေ
M1. ㉄⚛ㆇ៝⢻䈱ᒝൻਅ⸥ߩ੐㗄߇⑌ᱛߐࠇࠆ‫ޕ‬ 1㧚ⴊᶧ࠼࡯ࡇࡦࠣ‫ⴊޕ‬ᶧ࠼࡯ࡇࡦࠣߣߪ‫⥄ޔ‬Ꮖⴊ‫ޔ‬ห⒳ⴊ‫⇣ޔ‬⒳ⴊ෶ߪߔߴߡߩ⿒ⴊ⃿⵾೷ࠍᛩਈ
ߔࠆߎߣ‫ޕ‬ 2㧚㉄⚛៨ข߿㉄⚛ㆇ៝㧘㉄⚛ଏ⛎ࠍੱὑ⊛ߦଦㅴߔࠆߎߣ㧔ㆊࡈ࡞ࠝࡠൻว‛‫࡜ࠪࠠࡠࡊࠔࡈࠛޔ‬࡯࡞(RSR13)‫ୃޔ‬㘼ࡋࡕࠣࡠࡆࡦ⵾೷㧔ࡋࡕࠣࡠࡆࡦࠍၮߦߒߚⴊᶧઍᦧ‛⾰‫ࡑߩࡦࡆࡠࠣࡕࡋޔ‬ࠗࠢࡠࠞࡊ࠮࡞⵾೷╬㧕߇฽߹ࠇࠆ߇‫ߦࠄࠇߎޔ‬㒢ቯߔࠆ߽ߩߢߪߥ޿㧕‫ޕ‬

M2. ൻቇ⊛䊶‛ℂ⊛ᠲ૞ 1㧚࠼࡯ࡇࡦࠣࠦࡦ࠻ࡠ࡯࡞ߢណขߐࠇߚᬌ૕ߩቢోᕈ෸߮᦭ലᕈࠍᄌൻߐߖࠆߚ߼ߦᡷߑࠎ෶ߪᡷ
ߑࠎߒࠃ߁ߣߔࠆߎߣߪ⑌ᱛߐࠇࠆ‫ޔ↪૶ߩ࡞࠹࡯࠹ࠞߪߦࠄࠇߎޕ‬ዩߩߔࠅᦧ߃‫ޔ‬ዩߩᡷᄌߥ
ߤ߇฽߹ࠇࠆ߇‫ߦࠄࠇߎޔ‬㒢ቯߔࠆ߽ߩߢߪߥ޿‫ޕ‬ 2㧚ᱜᒰߥක≮ⴕὑࠍ㒰߈‫ޔ‬㕒⣂ౝᵈ౉ߪ⑌ᱛߐࠇࠆ‫ޕ‬M3. ㆮવሶ䊄䊷䊏䊮䉫ᴦ≮એᄖߩ⋡⊛ߢ‫┹ޔ‬ᛛ⢻ജࠍ㜞߼ࠆน⢻ᕈߩ޽ࠆ⚦⢩‫ޔ‬ㆮવሶ‫ޔ‬ㆮવ࿃ሶ෶ߪㆮવሶ⊒⃻ߩୃ㘼ߪ⑌ᱛߐࠇࠆ‫ޕ‬7

SUBSTANCES AND METHODSPROHIBITED IN-COMPETITION
In addition to the categories S1 to S5 and M1 to M3 defined above,
the following categories are prohibited in competition:

PROHIBITED SUBSTANCES
S6. STIMULANTS
All stimulants (including both their (D- & L-) optical isomers where relevant) areprohibited, except imidazole derivatives for topical use and those stimulants
included in the 2007 Monitoring Program*.
Stimulants include:
adrenaline**,Adrafinil,

amfepramone,

amiphenazole,amphetamine,

amphetaminil,
benzphetamine,cathine***,benzylpiperazine,

clobenzorex,

cocaine,bromantan,
cropropamide,crotetamide,

cyclazodone,
dimethylamphetamine,ephedrine****,

etamivan,famprofazone,

fenbutrazate,

fenetylline,

etilamphetamine,

fenfluramine,

etilefrine,

fencamfamin,

fenproporex,

fencamine,

furfenorex,

heptaminol,
isometheptene,
levmethamfetamine,
meclofenoxate,

mefenorex,

methamphetamine (D-),

mephentermine,

methylenedioxyamphetamine,

methylenedioxymethamphetamine,
methylephedrine

****

,

mesocarb,

p-methylamphetamine,

methylphenidate,modafinil,

nikethamide,

norfenefrine,

octopamine,

ortetamine,

oxilofrine,

parahydroxyamphetamine,

pemoline,

pentetrazol,

phenpromethamine,

phentermine,

phenmetrazine,

norfenfluramine,

4-phenylpiracetam (carphedon),selegiline,

sibutramine,

prolintane,phendimetrazine,

propylhexedrine,

strychnine,tuaminoheptane and other substances with a similar chemical structure orsimilar biological effect(s).

8Τ㧚┹ᛛળᬌᩏߢ⑌ᱛኻ⽎ߣߥࠆ‛⾰࡮ᣇᴺ Э૨᳍Ძ᳸᳍ᲯŴ᳇Ძ᳸᳇ᲭƴьƑƯŴɦᚡƷǫȆǴȪȸƸᇤ২˟ƴƓƍƯᅠഥƞǕǔŵࢲએ࿜૏
S6 ⥝ᅗ⮎
ߔߴߡߩ⥝ᅗ⮎㧔㑐ㅪߒߚߘߩశቇ⇣ᕈ૕㧔D ૕෸߮ L ૕㧕߽฽߼ߡ㧕ߪ‫ޔ‬ዪᚲ૶↪ߐࠇࠆࠗࡒ࠳࠱
࡯࡞⺃ዉ૕ߣ 2007 ᐕ⋙ⷞࡊࡠࠣ࡜ࡓ*ߦ฽߹ࠇࠆ⮎‛ࠍ㒰޿ߡ‫⑌ޔ‬ᱛߐࠇࠆ‫ޕ‬ǢȉȩȕǣȋȫŴǢȉȬȊȪȳ**ŴǢȳȕǧȗȩȢȳŴǢȟȕǧȊǾȸȫŴǢȳȕǧǿȟȳŴ
ǢȳȕǧǿȟȋȫŴ
șȳǺȕǧǿȟȳŴșȳǸȫȔȚȩǸȳŴȖȭȞȳǿȳŴ
ǫȁȳ***ŴǯȭșȳǾȬȃǯǹŴǳǫǤȳŴǯȭȗȭȑȟȉŴǯȭȆǿȟȉŴ
ǷǯȩǾȉȳŴ
ǸȡȁȫǢȳȕǧǿȟȳŴ
ǨȕǧȉȪȳ****ŴǨǿȟȐȳŴǨȁȫǢȳȕǧǿȟȳŴǨȁȬȕȪȳŴ
ȕǡȳȗȭȕǡǾȳŴȕǧȳȖȈȩǼȸȈŴȕǧȳǫȳȕǡȟȳŴȕǧȳǫȟȳŴ
ȕǧȍȁȪȳŴȕǧȳȕȫȩȟȳŴȕǧȳȗȭȝȬȃǯǹŴȕȫȕǧȎȬȃǯǹŴ
ȘȗǿȟȎȸȫŴǤǽȡȆȗȆȳŴ
ȬȖȡǿȳȕǧǿȟȳŴ
ȡǯȭȕǧȎǭǻȸȈŴȡȕǧȎȬȃǯǹŴȡȕǧȳȆȫȟȳŴȡǽǫȫȖŴ
ȡǿȳȕǧǿȟȳᲢD˳ᲣŴȡȁȬȳǸǪǭǷǢȳȕǧǿȟȳŴ
ȡȁȬȳǸǪǭǷȡǿȳȕǧǿȟȳŴp-ȡȁȫǢȳȕǧǿȟȳŴ
ȡȁȫǨȕǧȉȪȳ****ŴȡȁȫȕǧȋȇȸȈŴȢȀȕǣȋȫŴ
ȋǱǿȟȉŴȎȫȕǧȍȕȪȳŴȎȫȕǧȳȕȫȩȟȳŴ
ǪǯȈȑȟȳŴǪȫȆǿȟȳŴǪǭǷȭȕȪȳŴ
ȑȩȒȉȭǭǷǢȳȕǧǿȟȳŴȚȢȪȳŴȚȳȆȈȩǾȸȫŴȕǧȳǸȡȈȩǸȳŴ
ȕǧȳȡȈȩǸȳŴȕǧȳȗȭȡǿȟȳŴȕǧȳȆȫȟȳŴ
4-ȕǧȋȫȔȩǻǿȠᲢǫȫȕǧȉȳᲣŴȗȭȪȳǿȳŴȗȭȔȫȘǭǻȉȪȳŴ
ǻȬǮȪȳŴǷȖȈȩȟȳŴǹȈȪǭȋȸȍŴȄǢȟȎȘȗȆȳ෸߮㘃ૃߩൻቇ᭴ㅧ෶ߪ㘃ૃߩ↢‛ቇ⊛ലᨐࠍ᦭ߔࠆ߽ߩ‫ޕ‬8

The following substances included in the 2007 Monitoring Program (bupropion,
caffeine, phenylephrine, phenylpropanolamine, pipradol, pseudoephedrine,
synephrine) are not considered as Prohibited Substances.
**
Adrenaline associated with local anaesthetic agents or by local administration(e.g. nasal, ophthalmologic) is not prohibited.
***
Cathine is prohibited when its concentration in urine is greater than 5
micrograms per milliliter.
****
Each of ephedrine and methylephedrine is prohibited when its
concentration in urine is greater than 10 micrograms per milliliter.
*

A stimulant not expressly mentioned as an example under this section should beconsidered as a Specified Substance only if the Athlete can establish that thesubstance is particularly susceptible to unintentional anti-doping rule violations
because of its general availability in medicinal products or is less likely to be
successfully abused as a doping agent.

S7. NARCOTICS
The following narcotics are prohibited:buprenorphine,

dextromoramide,

its derivatives,hydromorphone,

oxymorphone,pentazocine,diamorphine (heroin),methadone,

morphine,

fentanyl andoxycodone,

pethidine.

S8. CANNABINOIDS
Cannabinoids (e.g. hashish, marijuana) are prohibited.

S9. GLUCOCORTICOSTEROIDS
All glucocorticosteroids are prohibited when administered orally, rectally,
intravenously or intramuscularly. Their use requires a Therapeutic Use Exemption
approval.
Other routes of administration (intraarticular /periarticular/ peritendinous/
epidural/ intradermal injections and inhalation) require an Abbreviated
Therapeutic Use Exemption except as noted below.
Topicalpreparations
when
used
for
dermatological(including
iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival andperianal disorders are not prohibited and do not require any form of Therapeutic
Use Exemption.

9

****

2007 ᐕ⋙ⷞࡊࡠࠣ࡜ࡓߦ฽߹ࠇࠆ‛⾰㧔ࡉࡊࡠࡇࠝࡦ‫ࡊ࡞࠾ࠚࡈޔࡦ࡝ࡈ࡟࠾ࠚࡈޔࡦࠗࠚࡈࠞޔ‬ࡠࡄࡁ࡯࡞ࠕࡒࡦ‫ࡦ࡝ࡈࡀࠪޔࡦ࡝࠼ࠚࡈࠛ࠼ࠗ࠰ࡊޔ࡞࡯࠼࡜ࡊࡇޔ‬㧕ߪ⑌ᱛ‛⾰ߣߺߥߐߥ޿‫ޕ‬****ࠕ࠼࡟࠽࡝ࡦߪ‫ޔ‬ዪᚲ㤗㈮⮎ߣߩ૬↪޽ࠆ޿ߪዪᚲ૶↪㧔㥦‫╬⌒ޔ‬㧕ߩ႐ว‫⑌ޔ‬ᱛߐࠇߥ޿‫ޕ‬****ǫȁȳ㧧ዩਛỚᐲ 5ǋg/ml એ਄߇⑌ᱛ‫ޕ‬****ǨȕǧȉȪȳߣȡȁȫǨȕǧȉȪȳ㧧ዩਛỚᐲ 10 ǋg/ml એ਄߇⑌ᱛ‫ޕ‬ߎߩ࠮࡚ࠢࠪࡦߢ଀ߣߒߡ᣿⏕ߦ᜼ߍࠄࠇߡ޿ߥ޿⥝ᅗ⮎ߪ‫┹ޔ‬ᛛ⠪߇ߘߩ⮎‛߇ක⮎ຠߣߒߡᐢߊᏒ⽼ߐࠇ‫ޔ‬ᓥߞߡਇᵈᗧߢ࠼࡯ࡇࡦࠣⷙೣ㆑෻ࠍ․ߦ⿠ߎߒ߿ߔ޿⮎‛ߢ޽ࠆ‫‛ࠣࡦࡇ࡯࠼ߪ޿ࠆ޽ޔ‬⾰ߣߒߡߪᲧセ⊛ੂ↪ߐࠇࠆߎߣ߇ዋߥ޿⮎‛ߢ޽ࠆߎߣࠍ⸽᣿ߒߚ႐วߩߺ‫ޔ‬ᜰቯ‛⾰ߣߒߡ⠨ᘦߐࠇࠆߴ߈ߢ޽ࠆ‫ޕ‬S7 㤗⮎
ਅ⸥ߩ㤗⮎ߪ⑌ᱛߐࠇࠆ‫ޕ‬ȖȗȬȎȫȕǣȳŴȇǭǹȈȭȢȩȟȉŴǸǢȢȫȒȍᲢȘȭǤȳᲣŴȕǧȳǿȋȫӏƼᛔ‫˳ݰ‬ŴȒȉȭȢȫȕǩȳŴȡǵȉȳŴȢȫȒȍŴǪǭǷǳȉȳŴǪǭǷȢȫȕǩȳŴ
ȚȳǿǾǷȳŴȚȁǸȳŵ

S8 䉦䊮䊅䊎䊉䉟䊄ࠞࡦ࠽ࡆࡁࠗ࠼㧔ࡂࠪࠪࡘ‫╬࠽ࠔࡈ࡝ࡑޔ‬㧕ߪ⑌ᱛߐࠇࠆ‫ޕ‬

S9 ♧⾰䉮䊦䉼䉮䉟䊄♧⾰ࠦ࡞࠴ࠦࠗ࠼ߩ⚻ญ૶↪‫⋥⚻ޔ‬⣺૶↪‫ޔ‬㕒⣂ౝ૶↪‫╭ޔ‬⡺ౝ૶↪ߪߔߴߡ⑌ᱛߐࠇࠆ‫ߩࠄࠇߎޕ‬૶↪ߦ޽ߚߞߡߪ‫ޔ‬ᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߩᛚ⹺߇ᔅⷐߣߥࠆ‫ޕ‬ߘߩઁߩ૶↪⚻〝㧔㑐▵ౝ㧛㑐▵๟࿐㧛⣷๟࿐㧛⎬⤑ᄖ㧛⊹ౝᵈ౉߅ࠃ߮ๆ౉㧕ߦߟ޿ߡߪ‫ޔ‬ਅ⸥ߩ႐ว
ࠍ㒰߈‫⇛ޔ‬ᑼߩᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎߇ᔅⷐߣߥࠆ‫ޕ‬⊹⤏㧔ࠗࠝࡦ࠻ࡈࠜ࡟ࠪࠬ㧛ࡈࠜࡁࡈࠜ࡟ࠪࠬࠍ฽߻㧕‫ޔ‬⡊‫ޔ‬㥦‫ޔ⋡ޔ‬ญ⣧ౝ‫ޔ‬ᱤ⡺߅ࠃ߮⢂㐷๟࿐ߩ∔ᖚߦኻߔࠆዪᚲ⊛૶↪ߪ⑌ᱛߐࠇߕ‫ߟ߆ޔ‬ᴦ≮⋡⊛૶↪ߩㆡ↪ភ⟎ߩ޿߆ߥࠆ↳⺧߽ᔅⷐߣߒߥ޿‫ޕ‬

9

SUBSTANCES PROHIBITED IN PARTICULARSPORTS
P1. ALCOHOL
Alcohol (ethanol) is prohibited in-competition only, in the following sports.
Detection will be conducted by analysis of breath and/or blood. The doping
violation threshold (haematological values) for each Federation is reported inparenthesis.
•
•
•
•
•
•
•
•

Aeronautic (FAI)
Archery (FITA, IPC)
Automobile (FIA)
Boules (CMSB, IPC bowls)
Karate (WKF)
Modern Pentathlon (UIPM) for disciplines involving shooting
Motorcycling (FIM)
Powerboating (UIM)(0.20 g/L)
(0.10 g/L)
(0.10 g/L)
(0.10 g/L)
(0.10 g/L)
(0.10 g/L)
(0.10 g/L)
(0.30 g/L)

P2. BETA-BLOCKERS
Unless otherwise specified, beta-blockers are prohibited in-competition only, inthe following sports.
• Aeronautic (FAI)• Archery (FITA, IPC) (also prohibited out-of-competition)• Automobile (FIA)• Billiards (WCBS)• Bobsleigh (FIBT)• Boules (CMSB, IPC bowls)• Bridge (FMB)• Curling (WCF)• Gymnastics (FIG)• Motorcycling (FIM)• Modern Pentathlon (UIPM) for disciplines involving shooting• Nine-pin bowling (FIQ)• Sailing (ISAF) for match race helms only
• Shooting (ISSF, IPC) (also prohibited out-of-competition)• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe andsnowboard halfpipe/big air• Wrestling (FILA)

10Υ㧚․ቯ┹ᛛߦ߅޿ߡ⑌ᱛߐࠇࠆ‛⾰

P1. 䉝䊦䉮䊷䊦ਅ⸥ߩ┹ᛛߦ߅޿ߡ‫࡞࡯ࠦ࡞ࠕޔ‬㧔ࠛ࠲ࡁ࡯࡞㧕ߪ┹ᛛળᬌᩏߦ㒢ߞߡ⑌ᱛߐࠇࠆ‫ޕ‬ᬌ಴ᣇᴺߪ‫ޔ‬๭᳇ಽᨆ߹ߚߪⴊᶧಽᨆߢ޽ࠆ‫ࠣࡦࡇ࡯࠼ޕ‬㆑෻߇ᚑ┙ߔࠆ㑣୯㧔ⴊᶧߩ୯㧕ߪ┹ᛛ࿅૕ߏߣߦ㧔㧕ߢ⴫␜ߔࠆ‫ޕ‬⥶ⓨ䉴䊘䊷䉿䋨࿖㓙⥶ⓨㅪ⋖䋺㪝㪘㪠䋩㩷䋨㪇㪅㪉㪇㩷㪾㪆㫃䋩㩷䉝䊷䉼䉢䊥䊷䋨࿖㓙䉝䊷䉼䉢䊥䊷ㅪ⋖䋺㪝㪠㪫㪘䋬࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ䋺㪠㪧㪚䋩㩷䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷⥄േゞ䋨࿖㓙⥄േゞㅪ⋖䋺㪝㪠㪘䋩㩷䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷䊑䊷䊦䋨࿖㓙䉴䊘䊷䊦䊶䊄䊶䊑䊷䊦ㅪว䋺㪚㪤㪪㪙䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ㩷 䊨䊷䊮䊗䉡䊦䉴䋺㪠㪧㪚㩷㪹㫆㫎㫃㫊䋩㩷 䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷ⓨᚻ䋨਎⇇ⓨᚻ㆏ㅪ⋖㪑㪮㪢㪝䋩㩷䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷

ㄭઍ੖⒳䋨࿖㓙ㄭઍ੖⒳ㅪว䋺㪬㪠㪧㪤䋩኿᠄⒳೎䈮䈍䈇䈩㩷䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷䊝䊷䉺䊷䉰䉟䉪䊦䋨࿖㓙䊝䊷䉺䊷䉰䉟䉪䊦ㅪ⋖䋺㪝㪠㪤䋩㩷䋨㪇㪅㪈㪇㩷㪾㪆㫃䋩㩷䊌䊪䊷䊗䊷䊃䋨࿖㓙䊌䊪䊷䊗䊷䊃ㅪว䋺㪬㪠㪤䋩㩷䋨㪇㪅㪊㪇㩷㪾㪆㫃䋩㩷㩷

P2. 䊔䊷䉺ㆤᢿ⮎․Ბߩቯ߼߇޽ࠆ႐วࠍ㒰߈‫࠲࡯ࡌޔ‬ㆤᢿ⮎ߪ‫ޔ‬ਅ⸥ߩ┹ᛛ⒳⋡ߦ߅޿ߡ┹ᛛળᬌᩏߦ㒢ߞߡ⑌ᱛߐ
ࠇࠆ‫ޕ‬⥶ⓨ䉴䊘䊷䉿䋨࿖㓙⥶ⓨㅪ⋖䋺㪝㪘㪠䋩㩷䉝䊷䉼䉢䊥䊷䋨࿖㓙䉝䊷䉼䉢䊥䊷ㅪ⋖䋺㪝㪠㪫㪘䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ䋺㪠㪧㪚䋩㩿┹ᛛᄖ䈮䈍䈇䈩䉅⑌ᱛ䋩㩷⥄േゞ䋨࿖㓙⥄േゞㅪ⋖䋺㪝㪠㪘䋩㩷䊎䊥䊟䊷䊄䋨਎⇇䊎䊥䊟䊷䊄䊶䉴䊘䊷䉿ㅪว䋺㪮㪚㪙㩷䊗䊑䉴䊧䊷䋨࿖㓙䊗䊑䉴䊧䊷ㅪว䋺㪝㪠㪙㪫䋩㩷䊑䊷䊦䋨࿖㓙䉴䊘䊷䊦䊶䊄䊶䊑䊷䊦ㅪว䋺㪚㪤㪪㪙䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ㩷 䊨䊷䊮䊗䉡䊦䉴䋺㪠㪧㪚㩷㪹㫆㫎㫃㫊䋩㩷䊑䊥䉾䉳䋨਎⇇䊑䊥䉾䉳ㅪ⋖䋺㪝㪤㪙䋩㩷䉦䊷䊥䊮䉫䋨਎⇇䉦䊷䊥䊮䉫ㅪ⋖䋺㪮㪚㪝䋩㩷૕ᠲ䋨࿖㓙૕ᠲㅪ⋖䋺㪝㪠㪞䋩㩷䊝䊷䉺䊷䉰䉟䉪䊦䋨࿖㓙䊝䊷䉺䊷䉰䉟䉪䊦ㅪ⋖䋺㪝㪠㪤䋩㩷
ㄭઍ੖⒳䋨࿖㓙ㄭઍ੖⒳ㅪว䋺㪬㪠㪧㪤䋩኿᠄⒳೎䈮䈍䈇䈩㩷䊅䉟䊮䊏䊮䊗䉡䊥䊮䉫䋨࿖㓙䊗䉡䊥䊮䉫ㅪ⋖䋺㪝㪠㪨䋩㩷䉶䊷䊥䊮䉫䋨࿖㓙䉶䊷䊥䊮䉫ㅪ⋖䋺㪠㪪㪘㪝䋩䋭䊙䉾䉼䊧䊷䉴䈮䈍䈔䉎䊓䊦䊛䈱䉂㩷኿᠄䋨࿖㓙኿᠄ㅪ⋖䋺㪠㪪㪪㪝䇮࿖㓙䊌䊤䊥䊮䊏䉾䉪ᆔຬળ䋺㪠㪧㪚䋩䋨┹ᛛᄖ䈮䈍䈇䈩䉅⑌ᱛ䋩㩷䉴䉨䊷㪆䉴䊉䊷䊗䊷䊄䋨࿖㓙䉴䉨䊷ㅪ⋖䋺㪝㪠㪪䋩䋭䉳䊞䊮䊒䇮䊐䊥䊷䉴䉺䉟䊦䋨䉣䉝䊥䉝䊦㪆䊊䊷䊐䊌䉟䊒䋩䇮㩷䉴䊉䊷䊗䊷䊄䋨䊊䊷䊐䊌䉟䊒䋯䊎䉾䉫䉣䉝䊷䋩㩷䊧䉴䊥䊮䉫䋨࿖㓙䊧䉴䊥䊮䉫ㅪ⋖䋺㪝㪠㪣㪘䋩㩷

10Beta-blockers include, but are not limited to, the following:
acebutolol,

alprenolol,

atenolol,

betaxolol,bisoprolol,

bunolol,carteolol,

carvedilol,

celiprolol,

esmolol,labetalol,levobunolol,

metipranolol,

metoprolol,

nadolol,
oxprenolol,
pindolol,

propranolol,

sotalol,timolol.

11ࡌ࡯࠲ㆤᢿ⮎ߣߒߡߪ‫ޔ‬ਅ⸥ߩ߽ߩ߇฽߹ࠇࠆ߇‫ߦࠄࠇߎޔ‬㒢ቯߔࠆ߽ߩߢߪߥ޿‫ޕ‬ǢǻȖȈȭȸȫŴǢȫȗȬȎȭȸȫŴǢȆȎȭȸȫŴșǿǭǽȭȸȫŴȓǽȗȭȭȸȫŴȖȎȭȸȫŴǫȫȆǪȭȸȫŴǫȫșǸȭȸȫŴǻȪȗȭȭȸȫŴǨǹȢȭȸȫŴ
ȩșǿȭȸȫŴȬȜȖȎȭȸȫŴȡȁȗȩȎȭȸȫŴȡȈȗȭȭȸȫŴȊȉȭȸȫŴ
ǪǯǹȗȬȎȭȸȫŴȔȳȉȭȸȫŴȗȭȗȩȎȭȸȫŴǽǿȭȸȫŴ
ȁȢȭȸȫŵ

11

SPECIFIED SUBSTANCES*“Specified Substances”* are listed below:• All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide)
greater than 1000 ng/mL and clenbuterol;• Probenecid;• Cathine,

cropropamide,ephedrine,

crotetamide,

etamivan,famprofazone,
heptaminol,
isometheptene,
levmethamfetamine,
meclofenoxate,p-methylamphetamine,

nikethamide,

norfenefrine,

octopamine,

ortetamine,

phenpromethamine,
selegiline,

methylephedrine,

oxilofrine,

propylhexedrine,

sibutramine,tuaminoheptane,
and any other stimulant not expressly listed under section S6 for which the
Athlete establishes that it fulfils the conditions described in section S6;• Cannabinoids;• All Glucocorticosteroids;• Alcohol;• All Beta Blockers.
* “The Prohibited List may identify specified substances which are particularly
susceptible to unintentional anti-doping rule violations because of their generalavailability in medicinal products or which are less likely to be successfully abused
as doping agents.” A doping violation involving such substances may result in a
reduced sanction provided that the “…Athlete can establish that the Use of such a
specified substance was not intended to enhance sport performance…”

12Φ㧚ᜰቯ‛⾰ ‫ޟ‬ᜰቯ‛⾰*‫ޔߪޠ‬ਅ⸥ߩߣ߅ࠅߢ޽ࠆ‫ޕ‬࡮ ߔߴߡߩๆ౉ࡌ࡯࠲2 ૞↪⮎‫ޔ‬㧔1000ng/mLએ਄ߩࠨ࡞ࡉ࠲ࡕ࡯࡞㧔ࡈ࡝࡯ߣࠣ࡞ࠢࡠࡦ㉄ᛴว૕ߩỚᐲ㧕ߣࠢ࡟ࡦࡉ࠹ࡠ࡯࡞ࠍ㒰ߊ㧕㧧࡮ ࡊࡠࡌࡀࠪ࠼㧧࡮ ࠞ࠴ࡦ‫ޔ࠼ࡒ࠲࠹ࡠࠢޔ࠼ࡒࡄࡠࡊࡠࠢޔ‬ࠛࡈࠚ࠼࡝ࡦ‫ޔࡦࡃࡒ࠲ࠛޔ‬ࡈࠔࡦࡊࡠࡈࠔ࠱ࡦ‫ޔ‬ࡋࡊ࠲ࡒࡁ࡯࡞‫ޔ‬ࠗ࠰ࡔ࠹ࡊ࠹ࡦ‫ޔ‬࡟ࡉࡔ࠲ࡦࡈࠚ࠲ࡒࡦ‫ޔ‬ࡔࠢࡠࡈࠚࡁࠠ࠮࡯࠻‫ޔ‬p-ࡔ࠴࡞ࠕࡦࡈࠚ࠲ࡒࡦ‫ޔࡦ࡝࠼ࠚࡈࠛ࡞࠴ࡔޔ‬࠾ࠤ࠲ࡒ࠼‫ޔࡦ࡝ࡈࡀࠚࡈ࡞ࡁޔ‬ࠝࠢ࠻ࡄࡒࡦ‫ޔࡦ࡝ࡈࡠࠪࠠࠝޔࡦࡒ࠲࠹࡞ࠝޔ‬ࡈࠚࡦࡊࡠࡔ࠲ࡒࡦ‫ޔࡦ࡝࠼࠮ࠠࡋ࡞ࡇࡠࡊޔ‬࠮࡟ࠡ࡝ࡦ‫ޔࡦࡒ࡜࠻ࡉࠪޔ‬࠷ࠕࡒࡁࡋࡊ࠲ࡦ
෸߮ߘߩઁߩ⥝ᅗ⮎ߢ S6 ߦ᣿⏕ߦ⸥タߐࠇߡ߅ࠄߕ‫ޔ‬S6 ߦㅀߴߚ᧦ઙࠍḩߚߔߎߣࠍ┹ᛛ⠪߇⸽᣿ߒߚ⮎‛࡮ ࠞࡦ࠽ࡆࡁࠗ࠼㧧࡮ ߔߴߡߩ♧⾰ࠦ࡞࠴ࠦࠗ࠼㧧࡮ ࠕ࡞ࠦ࡯࡞㧧࡮ ߔߴߡߩࡌ࡯࠲ㆤᢿ⮎‫ޕ‬‫⑌ޟ‬ᱛ࡝ࠬ࠻ߢߪ‫ޔ‬ක⮎ຠߣߒߡᐢߊᏒ⽼ߐࠇ‫ޔ‬ᓥߞߡਇᵈᗧߢ࠼࡯ࡇࡦࠣⷙೣ㆑෻ࠍ⿠ߎߒ߿ߔ޿

⮎‛‫ߪߡߒߣ⾰‛ࠣࡦࡇ࡯࠼ߪ޿ࠆ޽ޔ‬Ყセ⊛ੂ↪ߐࠇࠆߎߣ߇ዋߥ޿⮎‛ࠍ‫ߦ․ޔ‬ᜰቯ‛⾰ߣߔࠆߎߣ߇ߢ߈ࠆ‫ࠍ⾰‛ߥ߁ࠃߩߘޕޠ‬฽߻࠼࡯ࡇࡦࠣ㆑෻ߢߪ‫ߩߎޟޔ‬⒳ߩᜰቯ‛⾰ߩ૶↪߇┹ᛛജะ਄ࠍ
⋡⊛ߣߒߚ߽ߩߢߥ޿ߎߣࠍ┹ᛛ⠪߇⸽᣿ߢ߈ࠆ‫ޠ‬႐วߦߪ೙ⵙಣ⟎ߪシᷫߐࠇࠆߎߣ߇޽ࠆ‫ޕ‬12

WORLD
ANTI-DOPING
AGENCYplay true

THE 2007 MONITORING PROGRAM*
The following substances are placed on the 2007 Monitoring Program:
1. Stimulants:

In-Competition Only: Bupropion, caffeine, phenylephrine,
phenylpropanolamine, pipradrol, pseudoephedrine,
synephrine.

2. Narcotics:

In-Competition Only: morphine/codeine ratio* The WADA Code (4.5) states: “WADA, in consultation with other Signatories andgovernments, shall establish a monitoring program regarding substances which are
not on the Prohibited List, but which WADA wishes to monitor in order to detect
patterns of misuse in sport.”

13



WORLD
ANTI-DOPING
AGENCYplay true઒⸶
 ᐕ⋙ⷞࡊࡠࠣ࡜ࡓ ਅ⸥ߩ‛⾰߇  ᐕ⋙ⷞࡊࡠࠣ࡜ࡓߦឝタߐࠇࠆ‫ޕ‬ᲫᲨᐻ‫ڠ‬ᕤᲴᇤ২˟౨௹Ʒǈ  ࡉࡊࡠࡇࠝࡦ‫ޔࡦ࡝ࡈ࡟࠾ࠚࡈޔࡦࠗࠚࡈࠞޔ‬ࡈࠚ࠾࡞ࡊࡠࡄࡁ࡯࡞ࠕࡒࡦ‫ޔࡦ࡝࠼ࠚࡈࠛ࠼ࠗ࠰ࡊޔ࡞࡯ࡠ࠼࡜ࡊࡇޔ‬ࠪࡀࡈ࡝ࡦ
ᲬᲨ᰺ ᕤᲴ

ᇤ২˟౨௹Ʒǈ  ࡕ࡞ࡅࡀ㧛ࠦ࠺ࠗࡦᲧ


*WADAⷙ⒟㧔4.5᧦㧕㧦⑌ᱛ࡝ࠬ࠻ߦឝタߐࠇߡ޿ߥ޿‛⾰ߩ߁ߜ‫┹ޔ‬ᛛߦ߅ߌࠆ⮎‛ੂ↪ࡄ࠲࡯ࡦࠍ

ᛠីߒߚᣇ߇ᓧ╷ߢ޽ࠆߣWADA߇್ᢿߒߚ߽ߩ߇޽ࠆ႐ว‫ޔ‬WADAߪ‫⟑ߩઁޔ‬ฬᒰ੐⠪෸߮ฦ࿖᡽ᐭ
ߣද⼏ߒߡᒰ⹥‛⾰ߦ㑐ߔࠆ⋙ⷞࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆ߽ߩߣߔࠆ‫ޕ‬

13

THE WORLD ANTI-DOPING CODE
The 2007 Prohibited List International Standardଲ ‫ ٮ‬ͺ ϋ Ι ¦ Ρ Ȝ ά ϋ Έ ܰ ೾!
3118 ා޺গςΑΠͅ‫࣭̳ͥ۾‬ष‫ܖ‬੔!

‫ޟ‬WADA code ߪ⧷ᢥ ߇ේᧄߣߥࠅ߹ߔ‫ⷙᧄޕ‬⒟ߩ⧷ᢥߣ๺ᢥߦᏅ⇣߇޽ࠆ႐วߦߪ‫⧷ޔ‬ᢥ߇ఝవߐࠇ߹ߔ‫ޕ‬‫ޠ‬

2007 ා 1 ࠮ 1 ඾อ࢘
2007 ᐕ 1 ᦬⊒ⴕ
⽷࿅ᴺੱ ᣣᧄࠕࡦ࠴࡮࠼࡯ࡇࡦࠣᯏ᭴

WORLD
ANTI-DOPING
AGENCY仮訳

play true

世界アンチ・ドーピング規程（The World Anti-doping Code）

2007年禁止リスト国際基準(The 2007 Prohibited List International Standard)（2007年１月１日版）(Update 1 January 2007)
本リストは、2007年１月１日に発効するスポーツ振興くじ助成事業

財団法人

日本アンチ・ドーピング機構